Navigation Links
IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
Date:8/27/2007

triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including statements regarding the Company's plans to collect, analyze and submit additional Phase 3 data in an amended NDA for L-MTP-PE and to respond to other matters raised by ODAC and the FDA, the Company's confidence that the proposed NDA amendment will provide substantial evidence for the continued regulatory approval process, the Company's belief that the supplemental data to be submitted in the amended NDA will overcome the need for additional trials, the review of the submissions for marketing approval of L-MTP-PE by the FDA and the EMEA, and the Company's goal of making L-MTP-PE available to patients as quickly as possible. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, the possibility that the Company may not be able to collect, analyze and submit additional data in an amendment to the NDA for L-MTP-PE by the first quarter of 2008, if at all, the possibility that such data will not support the benefit of L-MTP- PE in the treatment of non-metastatic osteosarcoma, will not allow a more robust analysis of L-MTP-PE, will not continue to support its overall survival benefit in osteosarcoma, and may not provide substantial evidence for the potential regulatory approval of L-MTP-PE, the timing of the FDA's and EMEA's review of the submissions for marketing approval of L-MTP-PE, the ability of the Company to respond to questions raise
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Boston’s Adult Stem Cell Technology Center, LLC ... stem cell biotechnologies. Currently the company holds seven ... patent applications currently under examination by the U.S. Patent ... of the most vexing problems in adult stem cell ... are difficult to identify; and they have been difficult ...
(Date:7/30/2014)... , July 30, 2014 Regulus Therapeutics ... company leading the discovery and development of innovative medicines ... results and highlights for the quarter ended June 30, ... financial markets close. Regulus will host ... 2014, at 5:00 pm Eastern Daylight Time to discuss ...
(Date:7/30/2014)... W. R. Grace & Co. (NYSE: ... REVELERIS® Prep purification system , a dual-mode instrument ... researchers to perform both flash and preparative liquid ... the REVELERIS® Prep purification system, researchers can easily ... a simple touch of the screen, giving them ...
(Date:7/30/2014)... July 30, 2014 A study presented ... safety and efficacy of CSL Behring,s C1 Inhibitor ... transplants in highly sensitized patients. C1-INH is a ... complement system. The study shows that ... in the levels of complement components 3 and ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Grace Launches New REVELERIS® Prep Purification System 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... 0 clinical testing has been gaining acceptance and ... development process in the years to come. The ... and technology dependence is also expected to result ... in this sector.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )"There is every ...
... Health Care Business Conference, an MBA-student organized event, will be held ... distinguished speakers and panelists from Healthcare Services, Investment, Pharma, Biotech, and ... ... 10, 2009 -- The 2009 Wharton Health Care Business Conference ...
... Feb. 10 DSM Biologics and Crucell N.V. (Euronext, ... today that they have entered into an agreement with ... Vendor Network. Under the terms of the agreement, Bioceros ... licensees of the PER.C6(R) cell line located in the ...
Cached Biology Technology:Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 2Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 314th Annual Wharton Health Care Business Conference to Feature CEOs from WebMD, McKesson, Humana and Given Imaging 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 3DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 4DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 5
(Date:7/31/2014)... LA Dr. Oren Tessler, Assistant Professor of Clinical ... of Medicine, is part of a team of plastic ... using a method to screen and select patients for ... of the patients who underwent this surgery to decompress ... got a bonus cosmetic eyelid surgery. The study, which ...
(Date:7/31/2014)... NXT-ID, Inc., (NXTD: OTCQB) a biometric authentication company ... and consumers wanting to learn more about its  ... on-air today, July 31 st . ... featured in a segment of NewsWatch, a weekly ... the History Channel, FYI Network today. ...
(Date:7/30/2014)... by the Red Queen in Lewis Carroll,s Through ... Illinois and National University of Singapore improved a ... evolve over decades to millions of years. , ... for competition, incorporates the "Red Queen Effect," an ... the 1970s, which suggests that organisms must constantly ...
Breaking Biology News(10 mins):Surgeons report significant migraine relief from cosmetic eyelid surgery technique 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 3Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... choices for our nation,s schoolchildren is a hot-button issue ... team of researchers from Cornell University have recently identified ... vegetables and salad items. Laura Smith, a researcher ... findings of the study "Convenience Drives Choice in School ...
... Inc. (Nasdaq: OKSB ), ("Southwest"), today announced that it has priced its ... the public of $12.50 per share for net proceeds of approximately ... size of approximately $40 million .  The offering is expected to close ... , , ...
... PHILADELPHIA , April 27 Mondre Energy, Inc. (MEI), a ... Exeter Associates to address a wide range of energy issues on behalf ... Power Plant Research Program works to ensure that Maryland meets ... , , ...
Cached Biology News:Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 2Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 3Mondre Energy Partnering with Exeter Associates to Address Energy Issues in Maryland 2
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
...
... pACHLT-A-BFP Baculovirus Transfer Vector is a derivative of ... gene for blue fluorescent protein (BFP), followed by ... (MCS).,Foreign genes are expressed as BFP-6xHis fusion proteins ... enzyme,sites (EcoR I, Stu I, Sac I, Not ...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Biology Products: